1Menter A.Pharmacokinetics and safety of tazarotene[J].J Am Acad Dermatol,2000,31-35.
2Hardman JG,Limbird LE,Gilman AG,et al.Goodman & gilman's the pharmacological basis of therapeutics[M].10th.ed.McGraw-Hill Companies,2001,1802.
3Chandraratna RAS.Tazarotene:the first receptor-selective topical retinoid for the treatment of psoriasis[J].J Am Acad Dermatol,1997,37:14.
4Zouboulis CC.Retinoids-which dermatological indications will benefit in the near future?[J].Skin Pharmacol Appl Skin Pharmacol,2001,14(5):303-15.
5Duvic M,Asano AT,Hager C,et al.The pathogenesis of psoriasis and the machanism of action of tazarotene[J].J Am Aced Dermatol,1998,39:129-133.
6Sturniolo MT,Dashti SR,Deucher A,et al.A novel tumor suppressor protein promotes kerationcyte terminal differentiation via activation of type I tramsglutaminase[J].J Biol Chem,2003,28:278(48):48066-48073.
7Wolf JE Jr.Potential anti-inflammatory effects of topical retinoid and retinoid analogues[J].Adv Ther,2002,19(3):109-118.
8Shalita RA,Chalker AK,Griffith RF,et al.Tazarotene gel is safe and effective in the treatment of acne vulgaris:a multicenter, double-blind,vehicle-controlled study[J].Clin Ther,1999,63:349-354.
9Kakita L.Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris[J].J Am Dermatol,2000,43:51-54.
10Leyden JJ, Tanghetti EA, Miller B,et al.Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris:double-blind randomized trial[J].Cutis,2002,69(2):12-19.
